LUNG TRANSPLANTATION

UNOS Slide Template

LUNG TRANSPLANTATIONAdult Recipients

JHLT.2013 Oct; 32(10): 965-9782013Donor and Recipient Characteristics

JHLT.2013 Oct; 32(10): 965-9782013Adult Lung TransplantsRecipient Age Distribution (Transplants: January 1985 June 2012)

JHLT.2013 Oct; 32(10): 965-97820133Adult Lung TransplantsRecipient Age Distribution by EraMedian age by era (years): 1985-1989 = 45; 1990-1994 = 47; 1995-1999 = 50; 2000-2005 = 53; 2006-6/2012 = 55;

JHLT.2013 Oct; 32(10): 965-9782013The age distribution of lung transplant recipients was compared between eras using a chi-square test.

4Adult Lung TransplantsRecipient Age Distribution by EraNumber of >65 : 2000-2005 = 3322006-6/2012 = 1,968p-value comparing percentages of >65 between eras < 0.0001

JHLT.2013 Oct; 32(10): 965-9782013The age distribution of lung transplant recipients was compared between the two eras using a chi-square test.

5Adult Lung TransplantsRecipient Age Distribution by Era Diagnosis: COPD/EmphysemaNumber of >65 : 2000-2005 = 1552006-6/2012 = 650p-value comparing percentages of >65 between eras < 0.0001


6Adult Lung TransplantsRecipient Age Distribution by Era Diagnosis: IPFNumber of >65 : 2000-2005 = 1382006-6/2012 = 1,061p-value comparing percentages of >65 between eras < 0.0001


7Adult Lung TransplantsRecipient Age Distribution by EraMedian age by era (years)1985-1994 = 471995-2004 = 512005-6/2012 = 55

JHLT.2013 Oct; 32(10): 965-9782013The age distribution of lung transplant recipients was compared between eras using a chi-square test. A significant p-value means that at least one of the groups is different than the others but it doesnt identify which group it is.

8Adult Lung TransplantsKaplan-Meier Survival by Procedure Type(Transplants: January 1994 June 2011)p < 0.0001

JHLT.2013 Oct; 32(10): 965-9782013Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients.

The median survival is the estimated time point at which 50% of all of the recipients have died. The conditional median survival is the estimated time point at which 50% of the recipients who survive to at least 1 year have died. Because the decline in survival is greatest during the first year following transplantation, the conditional survival provides a more realistic expectation of survival time for recipients who survive the early post-transplant period.

Survival rates were compared using the log-rank test statistic. 9Adult Lung TransplantsIndications (Transplants: January 1995 June 2012)DiagnosisSLT (N = 14,197)BLT (N = 23,384)TOTAL (N = 37,581)COPD/Emphysema6,312 (44.5%)6,290 (26.9%)12,602 (33.5%)Idiopathic Pulmonary Fibrosis4,872 (34.3%)4,032 (17.2%)8,904 (23.7%)Cystic Fibrosis229 (1.6%)6,002 (25.7%)6,231 (16.6%)Alpha-1753 (5.3%)1,429 (6.1%)2,182 (5.8%)Idiopathic Pulmonary Arterial Hypertension87 (0.6%)1,073 (4.6%)1,160 (3.1%)Pulmonary Fibrosis, Other563 (4.0%)820 (3.5%)1,383 (3.7%)Bronchiectasis59 (0.4%)956 (4.1%)1,015 (2.7%)Sarcoidosis265 (1.9%)689 (2.9%)954 (2.5%)Re-Transplant: Obliterative Bronchiolitis276 (1.9%)292 (1.2%)568 (1.5%)Connective Tissue Disease156 (1.1%)332 (1.4%)488 (1.3%)Obliterative Bronchiolitis (Not Re-Transplant)98 (0.7%)298 (1.3%)396 (1.1%)LAM136 (1.0%)255 (1.1%)391 (1.0%)Re-Transplant: Not Obliterative Bronchiolitis182 (1.3%)220 (0.9%)402 (1.1%)Congenital Heart Disease56 (0.4%)269 (1.2%)325 (0.9%)Cancer7 (0.0%)29 (0.1%)36 (0.1%)Other146 (1.0%)398 (1.7%)544 (1.4%)

JHLT.2013 Oct; 32(10): 965-9782013Transplants with unknown diagnoses are excluded from this tabulation.10Adult Lung TransplantsDistribution of Procedure Type for Major Indications by YearYear of TXAlpha-1COPDCystic FibrosisIPFIPAHDoubleSingleDoubleSingleDoubleSingleDoubleSingleDoubleSingle199746.453.627.572.592.67.421.578.590.39.7199848.251.830.269.893.66.419.180.98713199946.653.4287291.38.723.376.786.413.6200057.942.129.370.794.25.830.769.3937200159.940.130.269.893.96.131.268.89010200256.343.738.961.196.23.8356588.111.9200365.234.843.256.895.64.441.358.795.64.4200473.926.145.854.296.33.744.155.994.55.52005782249.450.697.32.745.954.192.67.4200672.827.258.341.798.51.546.753.31000200783.616.463.836.297.32.748.951.194.75.3200880.219.865.634.498.61.451.248.893.96.1200986.413.666.433.699.80.250.849.298.61.4201086.213.870.429.699.20.855.344.795.74.3201187.112.972.827.298.61.453.546.596.83.2

JHLT.2013 Oct; 32(10): 965-978201311Adult Lung Transplants Procedure Type within Indication, by Year

JHLT.2013 Oct; 32(10): 965-978201312Adult Lung Transplants Indications for Single Lung Transplants (Transplants: January 1995 June 2012)

JHLT.2013 Oct; 32(10): 965-978201313Adult Lung Transplants Indications for Bilateral/Double Lung Transplants (Transplants: January 1995 June 2012)

JHLT.2013 Oct; 32(10): 965-978201314Adult Lung TransplantsMajor Indications By Year (%)

JHLT.2013 Oct; 32(10): 965-978201315Adult Lung TransplantsMajor Indications By Year (Number)

JHLT.2013 Oct; 32(10): 965-978201316Adult Lung TransplantsAge Distribution By Location (Transplants: January 2000 June 2012)

JHLT.2013 Oct; 32(10): 965-978201317Adult Lung TransplantsDiagnosis Distribution By Location(Transplants: January 2000 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013Transplants with unknown diagnoses are excluded from this tabulation.

18Adult Lung TransplantsDiagnosis Distribution By Location and Era(Transplants: January 2000 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013Transplants with unknown diagnoses are excluded from this tabulation.

19Adult Lung Transplants Donor Age Distribution By Location(Transplants: January 2000 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013Transplants with unknown donor age are excluded from this tabulation.

20Post-Transplant Survival and Rejection

JHLT.2013 Oct; 32(10): 965-9782013Adult Lung TransplantsKaplan-Meier Survival by Era (Transplants: January 1988 June 2011)All pair-wise comparisons were significant at p 65.No pair-wise comparisons within age groups were significant at < 0.05 except for 50-65

JHLT.2013 Oct; 32(10): 965-9782013Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The median survival is the estimated time point at which 50% of all of the recipients have died.

Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Bonferroni method.26Adult Lung TransplantsKaplan-Meier Survival by Diagnosis Conditional on Survival to 3 Months (Transplants: January 1990 June 2011)No pair-wise comparisons with Sarcoidosis were significant at p < 0.05 except CF vs. Sarcoidosis (p = 0.006)All other pair-wise comparisons were significant at p < 0.05 except COPD vs. IPF and CF vs. IPAH

JHLT.2013 Oct; 32(10): 965-9782013Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. This figure shows survival conditional on survival to 3 months. Therefore, only patients surviving to at least 3 months were included in the calculation. The conditional median survival is the estimated time point at which 50% of the recipients who survive to at least 3 months have died.

Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffes method.

27Adult Lung TransplantsKaplan-Meier Survival by Diagnosis and Age Group Conditional on Survival to 3 Months (Transplants: January 1990 June 2011)All pair-wise comparisons within diagnosis groups were significant at p < 0.001No pair-wise comparisons within age groups were significant at < 0.05 except for 50-65


Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Bonferroni method.28Adult Lung TransplantsKaplan-Meier Survival by Diagnosis Conditional on Survival to 1 Year (Transplants: January 1990 June 2011)No pair-wise comparisons with IPAH and Sarcoidosis were significant at p < 0.05 except with COPD and IPFAll other pair-wise comparisons were significant at p < 0.001


Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffes method. 29Adult Lung TransplantsKaplan-Meier Survival by Diagnosis and Age Group Conditional on Survival to 1 Year (Transplants: January 1990 June 2011)All pair-wise comparisons within diagnosis groups were significant at p < 0.0001No pair-wise comparisons within age groups were significant at < 0.05


Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Bonferroni method.30Adult Lung Transplants Kaplan-Meier Survival By Procedure Type(Transplants: January 1990 June 2011) Diagnosis: Alpha-1 Antitrypsin Deficiencyp < 0.0001


Survival rates were compared using the log-rank test statistic.

31Adult Lung Transplants Kaplan-Meier Survival By Procedure Type(Transplants: January 1990 June 2011) Diagnosis: Alpha-1 Antitrypsin Deficiencyp = 0.0002


Survival rates were compared using the log-rank test statistic. A significant p-value means that at least one of the groups is different than the others but it doesnt identify which group it is.

32Adult Lung Transplants Kaplan-Meier Survival By Procedure Type(Transplants: January 1990 June 2011) Diagnosis: COPD/Emphysemap < 0.0001



33Adult Lung Transplants Kaplan-Meier Survival By Procedure Type(Transplants: January 1990 June 2011) Diagnosis: COPD/Emphysemap < 0.0001


Survival rates were compared using the log-rank test statistic. A significant p-value means that at least one of the groups is different than the others but it doesnt identify which group it is.34Adult Lung TransplantsKaplan-Meier Survival by Era and Age Group(Transplants: January 1998 June 2011) Diagnosis: COPD/EmphysemaAll pair-wise comparisons within eras were significant at p < 0.01 except 2005-6/2011 18-49 vs. 50-65No pair-wise comparisons within age groups were significant at < 0.05


Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Bonferroni method. Only pair-wise comparisons statistically significant at p < 0.05 are shown on the slide. 35Adult Lung TransplantsKaplan-Meier Survival by Era and Age Group Conditional on Survival to 1 Year (Transplants: January 1998 June 2011) Diagnosis: COPD/EmphysemaAll pair-wise comparisons within eras were significant at p < 0.05 except 2005-6/2011 18-49 vs. 50-65No pair-wise comparisons within age groups were significant at < 0.05

JHLT.2013 Oct; 32(10): 965-9782013Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. This figure shows survival conditional on survival to 12 months. Therefore, only patients surviving to at least 12 months were included in the calculation.

Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Bonferroni method.36Adult Lung Transplants Kaplan-Meier Survival By Procedure Type and Era(Transplants: January 1990 June 2011) Diagnosis: COPD/Emphysema, Single Lung1990-1997 vs. 1998-2004: p < 0.00011990-1997 vs. 2005-6/2011: p < 0.00011998-2004 vs. 2005-6/2011: p = 0.9991



37Adult Lung Transplants Kaplan-Meier Survival By Procedure Type and Era(Transplants: January 1990 June 2011) Diagnosis: COPD/Emphysema, Double Lung1990-1997 vs. 1998-2004: p = 0.00661990-1997 vs. 2005-6/2011: p = 0.00891998-2004 vs. 2005-6/2011: p = 0.9983



38Adult Lung Transplants Kaplan-Meier Survival By Procedure Type(Transplants: January 1990 June 2011) Diagnosis: Idiopathic Pulmonary Fibrosisp < 0.0001



39Adult Lung TransplantsKaplan-Meier Survival by Era and Age Group(Transplants: January 1998 June 2011) Diagnosis: Idiopathic Pulmonary FibrosisAll pair-wise comparisons within eras were significant at p < 0.05 except 1998-2004 50-65 vs. >65 and 2005-6/2011 50-65 vs. >65No pair-wise comparisons within age groups were significant at < 0.05 except for 50-65


Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Bonferroni method. 40Adult Lung TransplantsKaplan-Meier Survival by Era and Age Group Conditional on Survival to 1 Year (Transplants: January 1998 June 2011) Diagnosis: Idiopathic Pulmonary FibrosisAll pair-wise comparisons within eras were significant at p < 0.05 except 1998-2004 50-65 vs. >65No pair-wise comparisons within age groups were significant at < 0.05

JHLT.2013 Oct; 32(10): 965-9782013Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. This figure shows survival conditional on survival to 12 months. Therefore, only patients surviving to at least 12 months were included in the calculation.

Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Bonferroni method.41Adult Lung Transplants Kaplan-Meier Survival By Procedure Type and Era(Transplants: January 1990 June 2011) Diagnosis: Idiopathic Pulmonary Fibrosis, Single Lung1990-1997 vs. 1998-2004: p = 0.03371990-1997 vs. 2005-6/2011: p = 0.00171998-2004 vs. 2005-6/2011: p = 0.4105



42Adult Lung Transplants Kaplan-Meier Survival By Procedure Type and Era(Transplants: January 1990 June 2011) Diagnosis: Idiopathic Pulmonary Fibrosis, Double Lung1990-1997 vs. 1998-2004: p = 0.00561990-1997 vs. 2005-6/2011: p < 0.00011998-2004 vs. 2005-6/2011: p = 0.0073



43Adult Lung Transplants Kaplan-Meier Survival By Procedure Type(Transplants: January 1990 June 2011) Diagnosis: Idiopathic Arterial Pulmonary Hypertensionp < 0.0001



44Adult Lung Transplants Kaplan-Meier Survival By Procedure Type and Era(Transplants: January 1990 June 2011) Diagnosis: Cystic Fibrosis, Double Lung1990-1997 vs. 1998-2004: p < 0.00011990-1997 vs. 2005-6/2011: p < 0.00011998-2004 vs. 2005-6/2011: p = 0.0668



45Adult Lung Transplants Kaplan-Meier Survival by Donor/Recipient CMV Status(Transplants: October 1999 June 2011)All pair-wise comparisons were significant at p < 0.05 except D(-)/R(+) vs. D(+)/R(+)



46Adult Lung Transplants Kaplan-Meier Survival by Donor/Recipient CMV Status and Era (Transplants: October 1999 June 2011)Era 1 = 10/1999-2004; Era 2 = 2005-6/2011Donor/Recipent CMV status: no 10/1999-2004 vs. 2005-6/2011 comparisons were significant at p < 0.05.10/1999-2004: D(-)/R(-) vs. D(+)/R(+) and D(-)/R(-) vs. D(+)/R(-) were significant at p < 0.052005-6/2011: D(-)/R(-) vs. D(+)/R(+), D(-)/R(-) vs. D(+)/R(-) and D(-)/R(+) vs. D(+)/R(-) were significant at p < 0.05


Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Bonferroni method.

47Adult Lung TransplantsPercentage Experiencing Treated Rejection between Discharge and 1-Year Follow-Up by Donor/Recipient CMV Status(Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upTreated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection.

JHLT.2013 Oct; 32(10): 965-9782013Comparisons were made using the chi-square statistic. Adjustments for multiple comparisons were done using Bonferroni method.

N represents those at risk for rejection.48Adult Lung TransplantsPercentage Experiencing Any Rejection between Discharge and 1-Year Follow-Up by Donor/Recipient CMV Status(Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upAny rejection = Recipient was reported to (1) have at least one acute rejection episode; or (2) have been hospitalized for rejection.


N represents those at risk for rejection.

49Adult Lung TransplantsPercentage Experiencing Treated Rejection between Discharge and 1-Year Follow-Up by Donor/Recipient CMV Status(Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upTreated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection.

JHLT.2013 Oct; 32(10): 965-9782013Comparisons were made using the chi-square statistic. Adjustments for multiple comparisons were done using Bonferroni method.50Adult Lung TransplantsPercentage Experiencing Any Rejection between Discharge and 1-Year Follow-Up by Donor/Recipient CMV Status(Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upAny rejection = Recipient was reported to (1) have at least one acute rejection episode; or (2) have been hospitalized for rejection.

JHLT.2013 Oct; 32(10): 965-9782013Comparisons were made using the chi-square statistic. Adjustments for multiple comparisons were done using Bonferroni method.51Functional and Employment Status and Rehospitalization Post-Transplant

JHLT.2013 Oct; 32(10): 965-9782013Adult Lung TransplantsFunctional Status of Surviving Recipients (Follow-ups: March 2005 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013Functional status is collected using Karnofsky score for adult recipients and Lansky score for pediatric recipients.

This figure shows the functional status reported on the 1-year, 2-year and 3-year annual follow-ups. Because all follow-ups between March 2005 and June 2012 were included, the bars do not include the same patients.53Adult Lung TransplantsEmployment Status of Surviving Recipients (Follow-ups: April 1994 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013This figure shows the employment status reported on the 1-year, 3-year and 5-year annual follow-ups. Because all follow-ups between April 1994 and June 2012 were included, the bars do not include the same patients.54Adult Lung TransplantsRehospitalization Post-transplant of Surviving Recipients (Follow-ups: April 1994 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013This figure shows the hospitalizations reported on the 1-year, 3-year, 5-year and 10-year annual follow-ups, representing the hospitalizations between discharge and 1 year, between the 2-year and 3-year follow-up, and between the 4-year and 5-year follow-up, respectively. Because all follow-ups between April 1994 and June 2012 were included, the bars do not include the same patients.55Induction and Maintenance Immunosuppression

JHLT.2013 Oct; 32(10): 965-9782013Adult Lung TransplantsInduction Immunosuppression Analysis limited to patients receiving prednisone(Transplants: January 2002 June 2012)Analysis is limited to patients who were alive at the time of the discharge

JHLT.2013 Oct; 32(10): 965-978201357Adult Lung TransplantsInduction ImmunosuppressionAnalysis limited to patients receiving prednisone(Transplants: 2002, 2006 and January 2012 June 2012)Analysis is limited to patients who were alive at the time of the discharge

JHLT.2013 Oct; 32(10): 965-978201358Adult Lung TransplantsInduction Immunosuppression Analysis limited to patients receiving prednisone(Transplants: January 2000 December 2011)

Analysis is limited to patients who were alive at the time of the discharge

JHLT.2013 Oct; 32(10): 965-978201359Adult Lung Transplants Survival by Induction Usage Conditional on Survival to 14 Days (Transplants: April 1994 June 2011)p < 0.0001N at risk at 5 years = 3,809


Survival rates were compared using the log-rank test statistic.60Adult Lung Transplants Survival by Induction Usage Conditional on Survival to 14 Days (Transplants: January 2000 June 2011)p < 0.0001N at risk at 5 years = 2,254


Survival rates were compared using the log-rank test statistic.61Adult Lung TransplantsMaintenance Immunosuppression at Time of Follow-upAnalysis limited to patients receiving prednisone(Follow-ups: January 2002 June 2012)Analysis is limited to patients who were alive at the time of the follow-up

JHLT.2013 Oct; 32(10): 965-9782013This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year and 5-year annual follow-up forms. To provide a snapshot of current practice, only follow-ups occurring between January 2002 and June 2012 were included. Therefore, this figure does not represent changes in practice between the 1-year follow-up and 5-year follow-up on a cohort of patients. The patients in the 1-year tabulation are not the same patients as in the 5-year tabulation.62Analysis is limited to patients who were alive at the time of the dischargeAdult Lung TransplantsMaintenance Immunosuppression at Time of Follow-upAnalysis limited to patients receiving prednisone(Follow-ups: January 2002 June 2012)NOTE: Different patients are analyzed in Year 1 and Year 5

JHLT.2013 Oct; 32(10): 965-9782013This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year and 5-year annual follow-up forms. To provide a snapshot of current practice, only follow-ups occurring between January 2002 and June 2012 were included. Therefore, this figure does not represent changes in practice between the 1-year follow-up and 5-year follow-up on a cohort of patients. The patients in the 1-year tabulation are not the same patients as in the 5-year tabulation.

63Adult Lung Transplants Maintenance Immunosuppression at Time of 1 Year Follow-upAnalysis limited to patients receiving prednisone(Follow-ups: 2002, 2006 and July 2011 June 2012)Analysis is limited to patients who were alive at the time of the follow-upNOTE: Different patients are analyzed in each time frame

JHLT.2013 Oct; 32(10): 965-9782013This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year annual follow-up forms. As different patients were transplanted each year this figure does not represent changes in immunosuppression for individual patients but may represent changes in practice.64Adult Lung Transplants Maintenance Immunosuppression at Time of Follow-upAnalysis limited to patients receiving prednisone(Follow-ups: January 2002 June 2012)Analysis is limited to patients who were alive at the time of the follow-up

JHLT.2013 Oct; 32(10): 965-9782013This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year and 5-year annual follow-up forms. To provide a snapshot of current practice, only follow-ups occurring between January 2002 and June 2012 were included. Therefore, this figure does not represent changes in practice between the 1-year follow-up and 5-year follow-up on a cohort of patients. The patients in the 1-year tabulation are not the same patients as in the 5-year tabulation.65Adult Lung Transplants Maintenance Immunosuppression Drug Combinations at Time of Follow-up (Follow-ups: January 2002 June 2012)Analysis limited to patients receiving prednisoneAnalysis is limited to patients who were alive at the time of the follow-upNOTE: Different patients are analyzed in Year 1 and Year 5

JHLT.2013 Oct; 32(10): 965-9782013This figure shows the maintenance immunosuppression reported as being provided at the time of the 1-year and 5-year annual follow-up forms. To provide a snapshot of current practice, only follow-ups occurring between January 2002 and June 2012 were included. Therefore, this figure does not represent changes in practice between the 1-year follow-up and 5-year follow-up on a cohort of patients. The patients in the 1-year tabulation are not the same patients as in the 5-year tabulation.66Adult Lung TransplantsKaplan-Meier Survival by Maintenance Immunosuppression Combinations Conditional on Survival to 1 Year (Transplants: January 2000 June 2011) Analysis limited to patients receiving prednisone p < 0.0001

JHLT.2013 Oct; 32(10): 965-9782013Survival was calculated using the Kaplan-Meier method, which incorporates information from all transplants for whom any follow-up has been provided. Since many patients are still alive and some patients have been lost to follow-up, the survival rates are estimates rather than exact rates because the time of death is not known for all patients. The cohorts were conditioned on survival to 1 year, so that maintenance immunosuppression combinations use during the first year could be used as a stratification factor.

Survival rates were compared using the log-rank test statistic. A significant p-value means that at least one of the groups is different than the others but it doesnt identify which group it is. 67Adult Lung TransplantsKaplan-Meier Survival by Maintenance Immunosuppression Combinations Conditional on Survival to 1 Year (Transplants: January 2000 June 2011) Analysis limited to patients receiving prednisone Diagnosis: COPD/Emphysemap = 0.0063


Survival rates were compared using the log-rank test statistic. A significant p-value means that at least one of the groups is different than the others but it doesnt identify which group it is. 68Adult Lung TransplantsKaplan-Meier Survival by Maintenance Immunosuppression Combinations Conditional on Survival to 1 Year (Transplants: January 2000 June 2011) Analysis limited to patients receiving prednisone Diagnosis: Idiopathic Pulmonary Fibrosisp = 0.0078


Survival rates were compared using the log-rank test statistic. A significant p-value means that at least one of the groups is different than the others but it doesnt identify which group it is. 69Adult Lung TransplantsKaplan-Meier Survival by Maintenance Immunosuppression Combinations Conditional on Survival to 1 Year (Transplants: January 2000 June 2011) Analysis limited to patients receiving prednisone Diagnosis: Cystic Fibrosisp = 0.4406


Survival rates were compared using the log-rank test statistic. A significant p-value means that at least one of the groups is different than the others but it doesnt identify which group it is. 70Adult Lung Transplants Percentage Experiencing Treated Rejection between Discharge and 1-Year Follow-Up (Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upTreated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection.No pair-wise comparisons were significant at < 0.05 except 18-34 vs. 35-49 and 18-34 vs. 60-65



71Adult Lung Transplants Percentage Experiencing Rejection between Discharge and 1-Year Follow-Up (Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upNo rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents.No pair-wise comparisons were significant at < 0.05 except 18-34 vs. 60-65



72Adult Lung Transplants Percentage Experiencing Treated Rejection between Discharge and 1-Year Follow-Up by Type of Induction (Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upTreated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection.No pair-wise comparisons were significant at p < 0.05 except No induction vs. IL-2R and IL-2R vs. Alemtuzumab


73Adult Lung Transplants Percentage Experiencing Rejection between Discharge and 1-Year Follow-Up by Type of Induction (Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upNo rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents.No pair-wise comparisons were significant at p < 0.05 except No induction vs. IL-2R and IL-2R vs. Alemtuzumab



74Adult Lung Transplants Percentage Experiencing Treated Rejection between Discharge and 1-Year Follow-Up by Type of Induction (Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upTreated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection.



75Adult Lung Transplants Percentage Experiencing Rejection between Discharge and 1-Year Follow-Up by Type of Induction (Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upNo rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents.



76Adult Lung Transplants Percentage Experiencing Treated Rejection between Discharge and 1-Year Follow-Up by Maintenance Immunosuppression(Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upTreated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection.



77Adult Lung Transplants Percentage Experiencing Rejection between Discharge and 1-Year Follow-Up by Maintenance Immunosuppression(Follow-ups: July 2004 June 2012)Analysis is limited to patients who were alive at the time of the follow-upNo rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents.





















84Post-Transplant Morbidities

JHLT.2013 Oct; 32(10): 965-9782013Adult Lung TransplantsCumulative Morbidity Rates in Survivors within 1 Year Post-Transplant (Follow-ups: April 1994 June 2012)OutcomeFollow-ups: April 1994 June 2003Follow-ups: July 2003 June 2012Within 1 YearTotal number with known responseWithin 1 YearTotal number with known responseHypertension 50.7%(N = 6,021)52.4%(N = 9,246)Renal Dysfunction26.1%(N = 6,012)21.8%(N = 11,279) Abnormal Creatinine 2.5 mg/dl15.9%16.5% Creatinine > 2.5 mg/dl8.3%3.6% Chronic Dialysis1.9%1.6% Renal Transplant0.0%0.1%Hyperlipidemia16.5%(N = 6,292)31.3%(N = 9,683)Diabetes20.1%(N = 5,987)27.0%(N = 11,240)Bronchiolitis Obliterans Syndrome9.4%(N = 5,624)9.5%(N = 10,640)

JHLT.2013 Oct; 32(10): 965-9782013This table shows the percentage of patients experiencing various morbidities as reported on the 1-year annual follow-up form. The percentages are based on patients with known responses. Because the outcomes are reported to be unknown at different rates the number with known responses for each outcome are also provided.86Adult Lung TransplantsCumulative Morbidity Rates in Survivors within 1 Year Post-Transplant (Follow-ups: April 1994 June 2012)OutcomeAge: 18-65 yearsAge: >65 yearsWithin 1 YearTotal number with known responseWithin 1 YearTotal number with known responseHypertension 51.4%(N = 14,128)55.7%(N = 1,139)Renal Dysfunction23.3%(N = 15,856)23.6%(N = 1,435) Abnormal Creatinine 2.5 mg/dl16.3%16.1% Creatinine > 2.5 mg/dl5.3%4.5% Chronic Dialysis1.6%2.9% Renal Transplant0.1%0.0%Hyperlipidemia24.5%(N = 14,778)38.1%(N = 1,197)Diabetes24.9%(N = 15,798)21.3%(N = 1,429)Bronchiolitis Obliterans Syndrome9.7%(N = 14,896)7.3%(N = 1,368)

JHLT.2013 Oct; 32(10): 965-9782013This table shows the percentage of patients experiencing various morbidities as reported on the 1-year annual follow-up form. The percentages are based on patients with known responses. Because the outcomes are reported to be unknown at different rates the number with known responses for each outcome are also provided.87Adult Lung TransplantsCumulative Morbidity Rates in Survivors within 1 and 5 YearsPost-Transplant (Follow-ups: April 1994 June 2012)Outcome

Within 1 YearTotal number with known responseWithin 5 YearsTotal number with known responseHypertension 51.7%(N = 15,267)82.4%(N = 4,503)Renal Dysfunction23.3%(N = 17,291)55.4%(N = 5,571) Abnormal Creatinine 2.5 mg/dl16.2%36.5% Creatinine > 2.5 mg/dl5.2%15.0% Chronic Dialysis1.7%3.2% Renal Transplant0.1%0.7%Hyperlipidemia25.5%(N = 15,975)58.4%(N = 4,856)Diabetes24.6%(N = 17,227)40.5%(N = 5,498)Bronchiolitis Obliterans Syndrome9.5%(N = 16,264)39.7%(N = 4,701)

JHLT.2013 Oct; 32(10): 965-9782013This table shows the percentage of patients experiencing various morbidities as reported on the 1-year annual follow-up form and within 5 years following transplantation. The percentages are based on patients with known responses. To reduce bias, only patients with responses reported on every follow-up through the 5-year annual follow-up were included in the 5-year analysis. Because the outcomes are reported to be unknown at different rates the number with known responses for each outcome are also provided.88Adult Lung TransplantsMorbidity Rates in Survivors within 10 Years Post-Transplant (Follow-ups: April 1994 June 2012)Outcome

Within 10 YearsTotal number with known responseRenal Dysfunction74.1%(N = 1,059) Abnormal Creatinine 2.5 mg/dl40.3% Creatinine > 2.5 mg/dl19.8% Chronic Dialysis8.7% Renal Transplant5.3%Bronchiolitis Obliterans Syndrome61.6%(N = 774)

JHLT.2013 Oct; 32(10): 965-9782013This table shows the percentage of patients experiencing various morbidities as reported within 10 years following transplantation. The percentages are based on patients with known responses. To reduce bias, only patients with responses reported on every follow-up through the 10-year annual follow-up were included. Because the outcomes are reported to be unknown at different rates the number with known responses for each outcome are also provided.89Adult Lung TransplantsFreedom from Bronchiolitis Obliterans SyndromeConditional on Survival to 14 days (Follow-ups: April 1994 June 2012)N at risk at 5 years = 2,614

JHLT.2013 Oct; 32(10): 965-9782013Freedom from bronchiolitis obliterans rates were computed using the Kaplan-Meier method.

The development of bronchiolitis obliterans is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the date of follow-up was used as the date of occurrence. Patients were included in the analysis until an unknown response for bronchiolitis obliterans was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for bronchiolitis obliterans at all follow-up time points.90Adult Lung TransplantsFreedom from Bronchiolitis Obliterans SyndromeStratified by Age GroupConditional on Survival to 14 days (Follow-ups: April 1994 June 2012)


The development of bronchiolitis obliterans is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the date of follow-up was used as the date of occurrence. Patients were included in the analysis until an unknown response for bronchiolitis obliterans was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for bronchiolitis obliterans at all follow-up time points.

Survival rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffes method.91Adult Lung TransplantsFreedom from Bronchiolitis Obliterans SyndromeStratified by DiagnosisConditional on Survival to 14 days (Follow-ups: April 1994 June 2012)No pair-wise comparisons were significant at p < 0.05



Rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffes method.92Adult Lung TransplantsFreedom from Bronchiolitis Obliterans SyndromeStratified by Induction UseConditional on Survival to 14 days (Follow-ups: April 1994 June 2012)N at risk at 5 years = 1,261 N at risk at 5 years = 1,015p < 0.0001



Rates were compared using the log-rank test statistic.93Adult Lung TransplantsFreedom from Bronchiolitis Obliterans SyndromeStratified by Induction UseConditional on Survival to 1 Year (Follow-ups: April 1994 June 2012)N at risk at 5 years = 1,261 N at risk at 5 years = 1,015p = 0.0001



Rates were compared using the log-rank test statistic.94Adult Lung TransplantsFreedom from Bronchiolitis Obliterans Syndromeby Donor/Recipient CMV StatusConditional on Survival to 14 Days (Follow-ups: April 1994 June 2012)N at risk = 18 N at risk = 21No pair-wise comparisons were significant at p < 0.05 except D(+)/R(-) vs. D(+)/R(+): p = 0.0326



Rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffes method.

95Adult Lung TransplantsFreedom from Bronchiolitis Obliterans Syndromeby Donor/Recipient CMV StatusConditional on Survival to 1 Year (Follow-ups: April 1994 June 2012)N at risk = 18 N at risk = 21No p-values were significant at p < 0.05



Rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffes method.96Adult Lung Transplants Freedom from Severe Renal Dysfunction* (Follow-ups: April 1994 June 2012)N at risk at 5 years = 3,838* Severe renal dysfunction = Creatinine > 2.5 mg/dl (221 mol/L), dialysis or renal transplant

JHLT.2013 Oct; 32(10): 965-9782013Freedom from severe renal dysfunction rates were computed using the Kaplan-Meier method.

The development of severe renal dysfunction is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the date of follow-up was used as the date of occurrence. Patients were included in the analysis until an unknown response for severe renal dysfunction was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for severe renal dysfunction at all follow-up time points.97Adult Lung TransplantsFreedom from Severe Renal Dysfunction* by Age Group (Follow-ups: April 1994 June 2012)* Severe renal dysfunction = Creatinine > 2.5 mg/dl (221 mol/L), dialysis or renal transplant


The development of severe renal dysfunction is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the date of follow-up was used as the date of occurrence. Patients were included in the analysis until an unknown response for severe renal dysfunction was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for severe renal dysfunction at all follow-up time points.

Rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffes method.98Adult Lung Transplants Freedom from Severe Renal Dysfunction* Conditional on Survival to 1 Year (Follow-ups: April 1994 June 2012)N at risk at 5 years = 3,838* Severe renal dysfunction = Creatinine > 2.5 mg/dl (221 mol/L), dialysis or renal transplant


The development of severe renal dysfunction is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the date of follow-up was used as the date of occurrence. Patients were included in the analysis until an unknown response for severe renal dysfunction was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for severe renal dysfunction at all follow-up time points.99Adult Lung TransplantsFreedom from Severe Renal Dysfunction* by Maintenance Immunosuppression Combinations at Discharge Conditional on Survival to 14 Days (Transplants: January 2000 June 2011)Analysis limited to patients receiving prednisone* Severe renal dysfunction = Creatinine > 2.5 mg/dl (221 mol/L), dialysis or renal transplantAll pair-wise comparisons with CyA + MMF/MPA were significant at p < 0.05. No other pair-wise comparisons were significant.


The development of severe renal dysfunction is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the date of follow-up was used as the date of occurrence. Patients were included in the analysis until an unknown response for severe renal dysfunction was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for severe renal dysfunction at all follow-up time points.

Rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Scheffes method.100Adult Lung Transplants Post Transplant Malignancy (Follow-ups: April 1994 June 2012) Cumulative Morbidity Rates in SurvivorsMalignancy/Type1-Year Survivors5-Year Survivors10-Year SurvivorsNo Malignancy17,068 (96.4%)5,040 (85.3%)883 (73.2%)Malignancy (all types combined)630 (3.6%)871 (14.7%)324 (26.8%)Malignancy Type*Skin199590226Lymphoma2439438Other16422793Type Not Reported2490* Recipients may have experienced more than one type of malignancy so sum of individual malignancy types may be greater than total number with malignancy.Other malignancies reported include: adenocarcinoma (2; 2; 1), bladder (2; 1; 0), lung (2; 4; 0), breast (1; 5; 2); prostate (0; 5; 1), cervical (1; 1; 0); liver (1; 1; 1); colon (1; 1; 0). Numbers in parentheses represent the number of reported cases within each time period.

JHLT.2013 Oct; 32(10): 965-9782013This table shows the percentage of patients with malignancies reported within 1 year, within 5 years and within 10 years following transplantation. The percentages are based on patients with known responses. To reduce bias, only patients with responses reported on every follow-up through the 5-year (10-year) annual follow-up were included in the 5-Year Survivors (10-Year Survivors) column.101Adult Lung Transplants Post Transplant Malignancy (Follow-ups: April 1994 June 2012) Cumulative Morbidity Rates in SurvivorsMalignancy/TypeAge: 18-65 yearsAge: >65 years1-Year Survivors5-Year Survivors1-Year Survivors5-Year SurvivorsNo Malignancy15,686 (96.6%)4,904 (85.9%)1,382 (94.5%)136 (67.0%)Malignancy (all types combined)549 (3.4%)804 (14.1%)81 (5.5%)67 (33.0%)Malignancy Type*Skin1635403650Lymphoma22290214Other1422092218Type Not Reported22920* Recipients may have experienced more than one type of malignancy so sum of individual malignancy types may be greater than total number with malignancy.

JHLT.2013 Oct; 32(10): 965-9782013This table shows the percentage of patients with malignancies reported within 1 year and within 5 years following transplantation. The percentages are based on patients with known responses. To reduce bias, only patients with responses reported on every follow-up through the 5-year annual follow-up were included in the 5-Year Survivors column.102Adult Lung Transplants Freedom from Malignancy (Follow-ups: April 1994 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013Freedom from malignancy rates were computed using the Kaplan-Meier method.

The development of malignancy is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the date of follow-up was used as the date of occurrence. Patients were included in the analysis until an unknown response for malignancy was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for malignancy at all follow-up time points.103Adult Lung Transplants Freedom from Malignancy by Age Group(Follow-ups: April 1994 June 2012)Pair-wise comparisons for all malignancy and skin were significant at p < 0.0001. No other pair-wise comparisons were significant at p < 0.05


The development of malignancy is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the date of follow-up was used as the date of occurrence. Patients were included in the analysis until an unknown response for malignancy was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for malignancy at all follow-up time points.

Rates were compared using the log-rank test statistic. Adjustments for multiple comparisons were done using Bonferroni method.104Adult Lung TransplantsFreedom from Malignancy Conditional on Survival to 1 Year (Follow-ups: April 1994 June 2012)


The development of malignancy is reported on annual follow-ups; a date of diagnosis is not provided. For this figure the date of follow-up was used as the date of occurrence. Patients were included in the analysis until an unknown response for malignancy was reported. Therefore, the rates seen here may differ from those reported in the cumulative prevalence slide which is based on only those patients with known responses for malignancy at all follow-up time points.

105Adult Lung Transplants% of Re-transplanted Recipients by Age Group (Transplants: January 2005 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013Adult Lung TransplantsCause of Death (Deaths: January 1992 June 2012)Cause of Death0-30 Days (N = 2,725)31 Days - 1 Year (N = 4,737) >1 Year - 3 Years (N = 4,315)>3 Years - 5 Years (N = 2,449)>5 Years 10 Years (N = 2,892)>10 Years (N = 899)Bronchiolitis8 (0.3%)216 (4.6%)1,119 (25.9%)710 (29.0%)734 (25.4%)188 (20.9%)Acute Rejection94 (3.4%)85 (1.8%)63 (1.5%)16 (0.7%)17 (0.6%)2 (0.2%)Lymphoma1 (0.0%)110 (2.3%)78 (1.8%)36 (1.5%)56 (1.9%)31 (3.4%)Malignancy, Non-Lymphoma5 (0.2%)134 (2.8%)329 (7.6%)266 (10.9%)379 (13.1%)113 (12.6%)CMV0112 (2.4%)42 (1.0%)7 (0.3%)4 (0.1%)1 (0.1%)Infection, Non-CMV535 (19.6%)1,687 (35.6%)971 (22.5%)471 (19.2%)523 (18.1%)154 (17.1%)Graft Failure672 (24.7%)790 (16.7%)807 (18.7%)440 (18.0%)515 (17.8%)156 (17.4%)Cardiovascular298 (10.9%)228 (4.8%)179 (4.1%)120 (4.9%)148 (5.1%)58 (6.5%)Technical301 (11.0%)162 (3.4%)38 (0.9%)14 (0.6%)24 (0.8%)8 (0.9%)Other811 (29.8%)1,213 (25.6%)689 (16.0%)369 (15.1%)492 (17.0%)188 (20.9%)Percentages represent % of deaths in the respective time period

JHLT.2013 Oct; 32(10): 965-9782013Only known causes of death are included in the tabulation.107Adult Lung TransplantsCause of Death Stratified by Age Group (Deaths: January 1992 June 2012)Age GroupCause of Death 0-30 Days31 Days - 1 Year >1 Year - 3 Years>3 Years - 5 Years>5 Years18-65Bronchiolitis8 (0.3%)201 (4.6%)1,065 (26.4%)691 (29.6%)910 (24.5%)Malignancy5 (0.2%)220 (5.0%)361 (8.9%)275 (11.8%)569 (15.3%)Infection514 (19.7%)1,686 (38.3%)957 (23.7%)450 (19.3%)665 (17.9%)Graft Failure644 (24.7%)724 (16.5%)757 (18.7%)422 (18.1%)661 (17.8%)Cardiovascular280 (10.7%)198 (4.5%)161 (4.0%)113 (4.8%)200 (5.4%)Technical290 (11.1%)157 (3.6%)38 (0.9%)14 (0.6%)32 (0.9%)All known causes2,6104,3974,0402,3333,721>65Bronchiolitis015 (4.4%)54 (19.6%)19 (16.4%)12 (17.1%)Malignancy1 (0.9%)24 (7.1%)46 (16.7%)27 (23.3%)10 (14.3%)Infection21 (18.3%)113 (33.2%)56 (20.4%)28 (24.1%)17 (24.3%)Graft Failure28 (24.3%)66 (19.4%)50 (18.2%)18 (15.5%)10 (14.3%)Cardiovascular18 (15.7%)30 (8.8%)18 (6.5%)7 (6.0%)6 (8.6%)Technical11 (9.6%)5 (1.5%)000All known causes11534027511670Acute rejection and other causes of death are not shown on the slide

JHLT.2013 Oct; 32(10): 965-9782013Only known causes of death are included in the tabulation.108Adult Lung Transplants Relative Incidence of Leading Causes of Death(Deaths: January 1992 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013Only known causes of death are included in the tabulation.109Adult Lung Transplants Relative Incidence of Leading Causes of Death by Age Group(Deaths: January 1992 June 2012)

JHLT.2013 Oct; 32(10): 965-9782013Only known causes of death are included in the tabulation.110Adult Lung TransplantsCause of Death Stratified by Donor/Recipient CMV Status (Deaths: January 1992 June 2012)Donor/ Recipient CMV StatusCAUSE OF DEATH0-30 Days31 Days - 1 Year >1 Year - 3 Years>3 Years - 5 Years>5 Years 10 Years>10 YearsD(-)/R(-)(N=1,714)BRONCHIOLITIS1 (0.5%)24 (6.0%)109 (24.8%)86 (32.1%)75 (24.5%)20 (18.2%)INFECTION, NON-CMV34 (18.1%)140 (34.8%)103 (23.4%)45 (16.8%)45 (14.7%)17 (15.5%)GRAFT FAILURE52 (27.7%)76 (18.9%)89 (20.2%)53 (19.8%)55 (18.0%)20 (18.2%)D(-)/R(+)(N=2,573)BRONCHIOLITIS3 (1.0%)32 (5.8%)163 (27.1%)106 (25.0%)151 (28.0%)38 (23.5%)INFECTION, NON-CMV58 (20.0%)214 (38.5%)141 (23.5%)96 (22.6%)92 (17.0%)28 (17.3%)GRAFT FAILURE82 (28.3%)93 (16.7%)112 (18.6%)69 (16.3%)105 (19.4%)28 (17.3%)D(+)/R(-)(N=2,295)BRONCHIOLITIS022 (3.3%)135 (22.0%)76 (24.1%)92 (25.9%)11 (11.8%)INFECTION, NON-CMV47 (18.3%)244 (36.9%)145 (23.6%)49 (15.6%)55 (15.5%)27 (29.0%)GRAFT FAILURE68 (26.5%)134 (20.3%)132 (21.5%)68 (21.6%)82 (23.1%)18 (19.4%)D(+)/R(+)(N=3,980)BRONCHIOLITIS1 (0.2%)49 (5.2%)271 (26.2%)170 (26.9%)170 (24.3%)39 (19.4%)INFECTION, NON-CMV81 (17.6%)339 (35.6%)226 (21.9%)126 (19.9%)128 (18.3%)27 (13.4%)GRAFT FAILURE141 (30.6%)205 (21.6%)198 (19.1%)125 (19.8%)138 (19.7%)40 (19.9%)

JHLT.2013 Oct; 32(10): 965-9782013Only known causes of death are included in the tabulation.111Multivariable Analyses

JHLT.2013 Oct; 32(10): 965-9782013Adult Lung Transplants (January 1999 June 2011)Risk Factors For 1 Year MortalityDIAGNOSISNHazard RatioP-value95% Confidence IntervalRetransplant 5851.69

Date post:	24-Feb-2016
Category:	Documents
Upload:	libra
View:	32 times
Download:	0 times

LUNG TRANSPLANTATION

Documents